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Abstract
The lack of available testing for SARS-CoV-2 has been one
of the primary challenges in the development and implementation of a comprehensive approach to infection prevention
and transmission in the United States (US). In response to
the need for increased testing capacities and capabilities,
the University of Louisville (UofL) Division of Infectious Diseases Center of Excellence for Research in Infectious Diseases (CERID) initiated the Louisville Coronavirus Surveillance Program, a comprehensive approach to surveillance
and testing of patients and healthcare workers. The first specimens were accepted on March 12, 2020, and parallel testing
was done using a high-capacity testing process at the Division of Infectious Diseases CLIA-certified laboratory to en-

sure concordant results. Steps in the testing process began
with validation of the testing methods and included database
development, acceptance of specimens, tracking and cataloging of specimens, testing, and reporting of results. Quality metrics were developed and used to prevent error and facilitate rapid reporting. Between March 12, 2020, and April
30, 2020, more than 5,500 tests were performed, identifying
more than 850 patients and healthcare workers infected with
COVID-19 in the Louisville, Kentucky, area. Although the process used high-capacity robotics for testing procedures, the
methods described here are applicable to settings employing
a variety of laboratory testing methods.

Background

engage new partnerships within and outside UofL to
build and rapidly implement a high capacity testing
process for the Louisville and surrounding areas in
Kentucky. For more than thirty years, researchers in
the Division of Infectious Diseases at the University of
Louisville have been involved in clinical research, primarily in the Louisville area’s nine adult and one pediatric acute care hospitals. The research program has
steadily grown and matured and in 2018, elements of
the program were aligned into a comprehensive clinical research enterprise. Figure 1 provides a graphic description of CERID and its components. Success of this
novel approach to testing would require reliance upon
existing relationships and partnerships with the area
hospital personnel and leadership coupled with the expertise of CERID personnel and the organizational capacity of that research enterprise.

The lack of available testing for SARS-CoV-2 has been
one of the primary challenges in the development and
implementation of a comprehensive approach to infection and infection transmission in the United States
(US). State health departments and the US Centers for
Disease Control and Prevention (CDC) were the first,
and the only, sites for testing in the US before midFebruary. Their capacities were far less than the need
and the demand for laboratory testing. In response
to the need for increased testing capacities and capabilities, the University of Louisville (UofL) Division
of Infectious Diseases, Center of Excellence for Research in Infectious Diseases (CERID) initiated a planning group aimed at development of a comprehensive
approach to surveillance and testing of patients and
healthcare workers. This approach would use the existing CERID research enterprise as the platform and

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10

In early January 2020, Luminex Corporation reached
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Figure 1. University of Louisville Center of Excellence for Research in Infectious Diseases (CERID) research enterprise.
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out to the UofL Division of Infectious Diseases (ID)
Laboratory asking to partner in development of a multiplex test for SARS-CoV-2. This partnership involved
assisting with the testing and validation of the real-time
PCR assay on the ARIES® instrument for submission to
the FDA for Emergency Use Authorization (EUA). This
work was completed by March 11, 2020 and a white
paper published describing these efforts.[1] Happening at the same time, in mid-February 2020, the University of Louisville’s Center for Predictive Medicine
(UofL-CPM) received a reference strain of the SARSCoV-2 virus from BEI resources to initiate basic research
geared toward understanding the characteristics of the
virus and develop a model system for identification.
The National Biocontainment Laboratory at the University of Texas Medical Branch in Galveston proposed
that the network of eleven regional biocontainment laboratories in the United States focus on development of
new testing methods in response to the outbreak and
limited testing capacities. As one of the regional biocontainment laboratories in that network, the UofLCPM responded to the initiative. Once the virus was
successfully grown and the real-time PCR assay developed by CDC was implemented in the UofL-CPM,
discussions began regarding how the research process
might facilitate laboratory testing for the virus using
the UofL-CPM high-capacity instrumentation. The potential for expanded access to testing was quickly recognized as a valuable addition to the limited testing
capabilities present throughout the Commonwealth of
Kentucky and the US. This expanded testing capability
formed the basis for a strategic surveillance approach
that was developed and published for broad access
through the University of Louisville Journal of Respiratory Infections on March 10, 2020.[2] The following
information outlines the implementation approach of
the Louisville COVID-19 Surveillance Program (LCSP)
process that began with the first specimen received on
March 10, 2020.
The objectives of this manuscript are to 1) describe the
steps in the Louisville COVID-19 Surveillance Program
(LCSP) process and 2) demonstrate the organizational
capacity needed to support the efforts.

Approach
The process used to implement the COVID-19 surveillance included developing and testing a proof of concept for the process, then implementing the process
continuous quality assessment and improvement at its
core.
Concept of the Testing Process
Planning for testing for patients hospitalized in the ten
Louisville area acute care hospitals began on February
22, 2020. A timeline of events relevant to the planning
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and implementation of the LCSP is shown in Table 1.
Before receipt of the first sample for testing, a process was conceptualized that would begin with the
collection of a sample from one of the ten Louisville
area hospitals, travel through the delivery, processing and testing steps, and end with interpretation and
sharing of results. Steps in the process were simulated to identify testing capabilities; validity, reliability, and capacity; process and capability gaps, opportunities for error that exist at any step, and opportunities for improvements and efficiencies. A member
of the LCSP team transported a representative sample
from one of the Louisville area hospitals to the COVID19 testing center. The sample was moved from receipt, through the testing process, and finally to storage in a biorepository. A first-generation database able
to capture patient information, specimen movement,
results, and biorepository storage was developed using REDCap™. Specimen handling and testing procedures were simulated to ensure safe and optimal laboratory practices. Interpretation of results and processes for communicating results and related information were tested through simulation and role-play. At
each phase in the process, team members cataloged the
steps, identified opportunities for error and efficiencies, documented proposed changes in the process and
the impact the changes, as well as quality indicators
necessary to ensure a standardized, safe and error-free
process. On March 10, 2020, the first specimens were
received for testing, signaling implementation of the
LCSP process.Implementation of the testing process
The process for developing and implementing a
surveillance testing approach using high-capacity,
high-throughput instrumentation included the following steps: 1) test instrument validation and result verification; 2) specimen database development; 3) specimen movement from hospitals to the testing site; 4)
data entry; 5) cataloging the specimen for movement
to the laboratory for processing; 6) assignment of the
specimen barcode; 7) specimen testing; 8) integration
of results from the testing instrument to the specimen
database; 9) analysis of test results; 10) communicating
test results; and 11) development and implementation
of quality measures.
1. Test Instrument validation and result verification:
One of the first steps in the process involved determination of existing capabilities and capacities for testing. For more than twenty years, the University of
Louisville Division of Infectious Diseases has operated
a CLIA-certified laboratory focused on clinical research
and diagnostic testing, serving as a reference laboratory. Luminex Corporation selected the laboratory as
one of the five US laboratory sites to validate their
ARIES® instrument and primers for submission to the
US Food and Drug Administration (FDA) as Emergency Use Authorization (EUA) test for COVID-19.[1]
3
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Table 1. Timeline of events relevant to planning and implementation of the Louisville Coronavirus Surveillance Program.

Date

CERID Activity

2/6/20–
2/14/20

2/14/20

Concept development for surveillance testing for
patients and healthcare workers.

2/24/20

First drafts of surveillance process protocol for IRB.

2/28/20

ID lab contacted by Luminex Corporation to be a site
evaluating ARIES platform for COVID-19 testing.
ARIES test kit validation completed and FDA white
paper submitted
Presentation of surveillance process to IRB
Submission of Louisville COVID-19 Surveillance
Program to IRB
IRB approval #20.0225
Testing of patient samples for COVID-19 in ID lab
and CPM lab in parallel
Daily review of ID lab and CPM results, then results
discussed with Chief Medical Officers of each
submitting hospital
Daily oral report and daily written reports provided to
Chief Medical Officers of each submitting hospital
Submission of first 5 positive and first 5 negative test
samples to the KDPH State Laboratory for
verification of results
Receipt of notification of results verification from the
KDPH State Laboratory
Samples being received from 10 Louisville hospitals
and 2 southern Indiana hospitals

3/3/20
3/7/20
3/8/20
3/9/20
3/10/20

3/11/20
3/13/20

3/14/20
3/15/20
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CPM Activity
Permission from CDC to receive SARS-CoV-2 virus
by CPM and initiation of a surveillance concept
within the US Regional Biosafety Laboratory
Network using CDC PCR assay
Proposed that the CPM can make RNA prep/real
time PCR automation for SARS-CoV2 virus with 96
samples/run.
Development of real time PCR with control plasmid,
harvesting and amplification of the CoV strain.

By 3/5/20, RT PCR available for use.

Testing of patient samples for COVID-19 in ID lab
and CPM lab in parallel.
Submission of results to ID reviewers at evenining
meetings held each day.

By close of the day on 3/15/2020 had tested 205
samples and identified 7 positives. 100%
congruence between ID lab and CPM lab results.
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Figure 2. REDCap database test request form page.
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The Luminex ARIES® test evaluated the sample for
SARS-CoV-2 detection using two viral genes and an
internal control (N1, N3 and human RNaseP). Per the
FDA, the ID laboratory was then required to submit the
first five positive and first five negative specimens to
the Kentucky Department for Public Health Division
of Laboratory Services for confirmation. This validation process was completed on March 13, 2020. Validation enabled the UofL ID laboratory to test up to
thirty samples in every three-hour run using the Luminex Aires® test. At the same time, the UofL-CPM
had begun testing the high-capacity high-throughput
robotic testing machine capable of testing 176 samples
in each four-hour run. This process used the CDC
primers N1, N2, and N3 in addition to the internal control human RNaseP. Use of the UofL-CPM testing capability brought immediate capacity, but there was a
need to evaluate results to ensure validity. Validation
was done by running parallel samples using both the
Luminex ARIES® test and the UofL-CPM CDC primers
in the first 200 samples received. The result of this parallel testing demonstrated 100% concordance with positive and negative results. With this concordance, we
had confidence in reliance upon the high-capacity test
instrument for all surveillance testing moving forward.
2.
Specimen database development: A REDCap
database was developed to capture all information necessary to track the specimen from receipt to result.
Figures 2–6 show the most current five database sections developed for this project including: 1) test request form, 2) barcode, 3) laboratory/biorepository, 4)
results, and 5) Louisville Coronavirus Surveillance Report. The initial database was improved repeatedly
during the first three weeks of operation to ensure information of importance to the hospitals, public health,
and other stakeholders was included. Individual reports were developed and made available on day one
of the project, as were access portals to facility results
via individual facility REDCap links. These links were
made available to these partners after the first three
weeks of operation. This approach facilitated the goal
of real-time access to the data for hospitals and public
health.
3. Specimen movement from hospitals to the testing site: Patient samples were collected by hospital
personnel and sent to their respective laboratories for
pickup by LCSP personnel. For facilities preferring
to courier their samples to the testing site, LCSP was
able to accept those specimens and move them into
the process. Hospitals were asked to package each
specimen in a biohazard bag with identifying information on the specimen container (e.g., patient label) and
complete a COVID-19 specimen test request form placing it in a pocket on the outside of the biohazard bag.
This form contained patient information such as name,
date of birth, medical record number; the type of specimen (e.g., nasopharyngeal); date and time of specimen
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10
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collection; and any other hospital-specific information
important to that facility (e.g., laboratory accession
number). LCSP personnel reported to a designated
pick-up area at each hospital laboratory three to four
times throughout the day (0700, 1100, 1200, and 1700)
seven days a week, to retrieve samples and transport
in temperature-controlled containers back to the testing site. Team members wore gloves during handling
of the specimen bags. Clear plastic transport containers with closable lids and biohazard labels were disinfected with a healthcare-grade registered (e.g., quaternary ammonium) germicide following each transport
event.
4. Data entry: Upon receipt of the specimen bags,
LCSP personnel entered data into REDCap by completing the test request and biorepository/laboratory sections (Figures 2 and 4). The data entry process consisted of teams of two researchers and two quality reviewers. One researcher entered data into REDCap and
the second researcher was responsible for handling the
specimen bag (Figure 7). The researcher handling the
specimen bag provided the information from the specimen test requisition form—or specimen tube label if no
requisition form was available—to the researcher entering the data. If no test requisition form accompanied the specimen, a generic form was completed at
that time. This facilitated data entry and quality processes. Specimen biohazard bags remained closed and
the specimen tube information was visualized through
the biohazard bag. The team member handling the
closed bag wore gloves and hands were washed after
glove removal. After completing the data entry process, the specimen tubes still inside the closed biohazard bags were placed back into the clear plastic lockable
container and taken to the biosafety cabinet area to begin the racking and cataloging process.
5. Cataloging the specimen for movement to the
laboratory for processing: The racking of tubes and
spreadsheet production process (cataloging) consisted
of teams of two researchers (#1 and #2) and one quality reviewer. The laboratory cataloging process involved the use of a biosafety cabinet (BSC, Level 2)
with controlled airflow and a protective sash that could
be lowered providing a safe work environment commonly referred to as “under the hood”. Once under
the BSC, the specimen bags were opened, and the specimen tubes were prepared for placement in the specimen tube racks. Researcher #1 handling the specimen tubes wore personal protective equipment including gown, gloves, and facemask. Researcher #1 would
remove the test requisition form from the sample bag
and verify that the patient demographic information on
the form matched information listed on the specimen
tube. Upon completion of this verification, researcher
#1 would write a unique serial tube number (1-88)
in three locations: cap of the sample, on the sample
tube itself, and the test requisition form. Researcher#1
6
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Figure 3. REDCap barcode page.

Figure 4. REDCap laboratory/biorespository page.
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Figure 5. REDCap results page.

Figure 6. REDCap Louisville Coronavirus Surveillance Program report page.
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Figure 7. Researchers entering data into REDCap from patient specimen.

Figure 8. Researchers racking tubes and cataloging specimen for processing.
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would then place that numbered tube into the test tube
rack in sequence. Tubes were racked in groups of 88
as the testing instrument used by the UofL-CPM analyzed 88 samples in each testing batch, in addition to
the spaces reserved for controls (Figure ??).
At the same time researcher #1 is working in the BSC,
researcher #2 would construct the specimen catalog.
An electronically shared Excel spreadsheet process was
used to develop that specimen catalog enabling realtime visual access for specimen location and quality
monitoring. Data in the spreadsheet included: current date, time of the testing run, collection date of the
specimen, tube number, REDCap identification number, name, date of birth, and a location for the barcode
that would be provided. Researcher #1 would read
aloud the patient’s name, date of birth, and write a tube
number (1-88) on the cap of the specimen sample as
well as the body of the sample. Researcher #2 entered
those data elements into the specimen catalog spreadsheet. The tube number provided a way to identify any
given tube if the tube was needed for additional testing.
Following completion of the process, the researcher #2
would work with the quality reviewer to perform a
quality crosscheck with the REDCap database and add
the patient’s unique identifying number (assigned in
REDCap) to the catalog. This would ensure that the patient specimen had been entered into REDCap and the
specimen used for testing was correct (e.g., nasopharyngeal swab versus sputum). At this point, the specimen cataloging process was complete. The specimens
were placed in a locked biohazard transport container
and transported to a designated area for the UofL-CPM
personnel to take possession of the samples for laboratory processing.
6. Assignment of the specimen barcode: The specimen barcoding process included application of a
unique barcode identifier to each specimen tube. This
unique barcode with human readable characters identified the location of the sample on the test plate and
linked the result to the individual patient. The specimen barcoding process required two laboratory technicians. The barcoding process began after the LCPS
team provided the completed specimen catalog spreadsheet to the UofL-CPM lab personnel. This important communication process confirmed that the sample tubes were prepared, a quality review of the REDCap data entry had been completed and the catalog
spreadsheet had been completed. Once verified, the
barcoding process could begin. Laboratory technician
#1 would work under the BSC in the laboratory area
where they would pick up the first tube from the rack
and call out the name on the tube. This would enable
technician #2 to crosscheck the specimen catalog and
apply the barcode to the specimen tube and the catalog sheet. (Figure 9) This would ensure that the same
bar code was assigned to the patient specimen tube, the
catalogue sheet, and to the aliquot from that specimen
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10
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tube that was placed into the test well. This process
continued until all 88 specimen tubes had been barcoded, the barcodes entered on the cataloging sheet,
and the aliquot placed into the test well. The specimen
catalog sheet was then given to LCSP personnel who
then scanned the barcode from the specimen catalogue
into REDCap (Figures 10 and 11). The alphanumeric
barcode would then be visible in REDCap as shown
in Table 3. Following completion of this process, two
quality team members performed a review of the barcode scans for each specimen in the run to ensure accuracy of the tube assignment and visibility of the barcode in REDCap.
7. Specimen testing: After barcoding, the UofL-CPM
staff assumed responsibility for the specimen and testing began in a biosafety level 2 laboratory with an enhanced biosafety practice. This area was chosen as
biosafety cabinets and space were readily available.
The two UofL-CPM personnel responsible for the specimen processing wore gowns, gloves, and facemasks.
UofL-CPM virology personnel opened specimen samples under a BSC, obtained an aliquot from the specimen tube, and pipetted it into the testing block. Samples were tested for SARS-CoV-2 with a real-time-PCR
assay detecting viral RNA. Samples (up to 100 µL) were
treated with Trizol reagent, which inactivated the virus
and released RNA from the sample. Then, the total
RNA in the sample was extracted and purified using
a magnetic beads-based method.
RNA extraction was performed using laboratory automation (Tecan Evo100 with MCA96) with a script developed in-house. Eighty-eight total samples were processed as a batch in a 96-well plate along with four
negative controls (healthy volunteers) and four positive controls (viral RNA extracted from in vitro culture). Detection of viral RNA in the extracted RNA
was performed with the real-time PCR technology with
the primer/probes (2019-nCoV CDC EUA Kit), developed by CDC and manufactured by IDT using a onestep master mix (TaqPath CG, Thermofisher). Realtime RT-PCR was conducted with QuantStudio7Pro in
a 384-well plate format. The human RNAse P gene was
used for an internal control to ensure human cells were
present and to detect any sample inhibition that might
be present. A Ct value less than 39 was considered as
positive for the target. While one technician worked
with the specimen, the second technician monitored
placement of the aliquot in the test well and assured the
assigned bar code was linked to the corresponding patient in the test instrument. Once completed, the original sample tubes were returned to the refrigerated area
for pickup by LCSP personnel.
8. Integration of results from the testing instrument
to the specimen database: After each testing cycle, the
instrument recorded results that were analyzed by the
principal virologist. Once satisfied with the quality of
the results and test process, the results were sent in
10
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Figure 9. Assignment of barcode.
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Figure 10. Scanning barcode into REDCap.

an Excel spreadsheet via internal secured email to the
LCSP biostatistics and informatics personnel for uploading into REDCap. This upload linked individual
results to their unique barcode and populated the Results section in REDCap for each patient.
9. Analysis of test results: LCSP personnel reviewed
the test result information provided by the virologist
using the specimen catalog spreadsheet to verify that
each result had linked to the correct patient barcode.
REDCap was programmed to assign a completion status for all results identified as “negative” or “invalid”.
Results identified as “inconclusive” would await another run using the original specimen (not the aliquot).
A second “inconclusive” result would be finalized. All
results finalized as “inconclusive” or “invalid” were
communicated to the submitting facility so they could
make the clinical determination as to whether a new
specimen should be collected and resubmitted for testing. All “positive” results required manual entry into
REDCap and completion of result verification as a final check to ensure there were no positive results entered in error. The completion work was done by one
of the Infectious Diseases faculty members with a quality partner to prevent patient/barcode identification errors (Figure 5).
10. Communicating test results The primary purpose
of the surveillance program was to identify patients
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10

with and without disease so healthcare personnel could
evaluate the necessity for isolation, use of personal protective equipment, and healthcare worker occupational
exposure assessment. Therefore, it was critical to ensure results were shared promptly with individuals
empowered to make local decisions. Results were reviewed as the principal virologist released them. This
process occurred at least once each day and sometimes
twice if multiple testing runs occurred. Results were
shared via telephone with the Chief Medical Officer
of each hospital facility the day results were received.
A written report with a cumulative list of all patients
tested from that facility was emailed the following day
using a secured and encrypted process. Included in
that report was a cover page with an explanation of
the test interpretation. This helped recipients understand what action was indicated in the event the result
was noted as “invalid” or “inconclusive”. A summary
report was also sent to the Kentucky Department for
Public Health and the local health departments (e.g.,
Louisville Metro Public Health and Wellness, Floyd
and Clark counties in neighboring southern Indiana).
Excel files of patient results were also sent to the laboratory contact at each facility so they could integrate
results into their separate electronic health record systems. Individual patient reports were not provided. By
week five of the project, a REDCap data portal was developed with access provided to each facility submit-
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Figure 11. Specimen catalog with barcodes.
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Figure 12. REDCap database portal view.

ting patient samples for testing. This portal access was
made available to a point person at each facility enabling them to have real-time access to finalized test
results (Figure 12).

patient settings. The CERID enterprise structure enabled quick access to trained personnel and organizational capacity. Having this structure in place enabled
the rapid implementation of a surveillance team and
process to address the COVID-19 pandemic.

11. Quality measures: Ensuring quality at every step
in the process involved identifying activities pronue
to error (e.g., manual data entry) as well as activities
that were subject to errors of high consequence (e.g.,
misidentification of specimen, barcoding error). Each
step in the process was evaluated to determine possible errors and a corresponding approach for quality
monitoring. Figure 9 provides a summary of the quality indicators for each process step. Specific personnel were assigned to the quality measurement function,
each serving as an independent evaluator of the process. These personnel were trained in each step of the
process and helped craft the indicators. Quality reports
were developed and shared with the LCSP teams as a
way of tracking process errors as well as identifying opportunities for quality improvement and efficiencies.

Operationalizing the surveillance process incorporated
use of each component of the CERID enterprise. A
brief description of those units and their responsibilities shown in Figure 1 are described below:

Organizational Capacity
The CERID research enterprise provides the framework and support necessary for a robust program focused on population-based clinical research capable of
studying health conditions present in patients receiving care in hospitals, long-term care facilities, and outULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10

The Data Management, Biostatistics, and Informatics
Units were responsible for working together to develop
the initial REDCap database and respond to improvements that resulted over the first five weeks of its use.
These three groups worked together to develop reports
and reporting processes as well as respond to technologic requests from hospitals, long-term care facilities
and public health concerning real-time, read-only data
access. This real time access required that individual
portals be developed so facilities could see only their
data while public health officials were able to access all
data.
The Implementation Unit was responsible for surveillance activities including specimen retrieval, data entry, cataloging, and barcoding. This group consisted of
personnel with specific training in clinical research and
all aspects of a standardized operational approach.
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Table 2. Quality indicators for each process step.

Process step

Quality Indicators

1. Test instrument validation and 1A.
result verification
2A.
2B.
2C.
2. Database development
2D.
2E.
2F.
2G.
3A.
3B.
3. Specimen movement from
3C.
hospitals to the testing site
3D.
3E.
4A.
4B.
4. Data entry
4C.
4D.
4E.
5A.
5B.
5C.
5. Cataloging the specimen for
5D.
movement to the laboratory for
5E.
processing
5F.
5G.
5H.
5I.
6A.
6B.
6C.
6D.
6E.
7A.
7B.
7. Specimen testing
7C.
7D.
8. Integration of results from the 8A.
testing instrument to the
8B.
specimen database
6. Assignment of the specimen
barcode

9. Analysis of test results

10. Communicating test results

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/10

9A.
9B.
10A.
10B.
10C.
10D.
10E.

Concordant results using two different test methods; one in CLIA-certified lab and
one in research lab
Manual entry restricted to demographic section
Dropdown options available for all data items
Portal access can be developed
Individual facility reports
Barcode capability
Result import acceptable
Phone friendly iOS and Android
Packaged appropriately for transport
Test request form accompanying each specimen
Test request form and specimen match
Specimen labelled
Specimen label legible
Correct spelling of patient name
Correct date of birth
Specimen assigned to correct facility
Correct specimen type
Identity of data entry personnel
Appropriate PPE worn by personnel
All work performed in biosafety cabinet
Specimen tubes numbered
Specimen tubes in rack
Catalog completed with all data elements entered
Catalog data elements accurate
Tubes transported to CMP refrigerator in closed container to await testing
PPE removed, placed in biohazard bag, hand hygiene by personnel
Specimen catalog placed with tubes in CPM refrigerator to await barcode
placement
Barcode placed on specimen catalog sheet by CPM personnel
Barcode sheet retrieved by LCSP personnel
Barcode scanned into REDCap
Barcode verified to ensure capture in REDCap and on correct patient
Multiple barcode acceptance
Process supports standard test run times
Result concordance with parallel testing
Definitive results
Process demonstrates accepted good laboratory practices
Imports accepted by Excel
Data imports allowing finalization of select results
Definitive results
Reliable barcode links
Direct communication with hospital chief medical officers
Direct communication with public health officials
Direct communication with facility point person
Portal available with file download options
Printed report option
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Laboratory Unit personnel possessed expertise in the
handling and management of clinical and research
specimens, so they were quickly able to transition their
work from clinical research studies to assisting with
specimen management and handoff to the UofL-CPM
testing team. These personnel were also critical in developing an understanding of good laboratory practices as are present in the ID Division Reference Laboratory. In addition, these personnel provided the necessary expertise in understanding test results, their limitations, and approaches for providing useful information back to the participating facilities and healthcare
personnel.
The Biorepository Unit was responsible for developing
the process to track and maintain all specimen in the
event it was necessary to retest. This unit also managed
the process for freezing all positive specimens for validation or subsequent re-testing. The REDCap database
provided the opportunity to document and catalogue
precise specimen location for easy retrieval. (Figure 5)
Members of the Quality Assurance Unit were responsible for identifying steps in the process where error
could occur. This included identification of steps that
were prone to error and situations where error occurred or where there was a ‘near miss’. This team
provided reports of those occurrences back to the team
leader and each were addressed immediately. This
work involved process change (e.g., a numbering system added to tubes), error prevention (e.g., implementing a 3-day save the tube procedure), and identifying
near miss situations (e.g., individual specimen identification instead of multiple samples under a single
REDCap identification number). With any change, staff
were re-trained.
The Community and University Outreach Units worked
with researchers across the University of Louisville
campuses and the community to identify their areas
of expertise and interest in surveillance program participation as well as designing research questions. Researchers in the Speed School of Engineering worked to
develop products that could use the 3D printing capability to address care-related capacity such as production of face shields for nurses and printing of an alternative swab in light of the shortages in that critical supply.
The Medical Writing Unit and the Peer-Review Journals
Unit continued their responsibility for disseminating
knowledge gained as part of the COVID-19 response.
As new information was learned regarding the process,
a mentored writing and publication process began with
articles submitted for peer-review in both the Journal
of Respiratory Infections and the Journal of Refugee and
Global Health.
Members of the Marketing Unit served as the communi-
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cation link with local media, community partners, and
public health so there was ongoing awareness of activities and findings. For example, this Unit was responsible for working with radio, television, and other social
media connections interested in the surveillance operation and findings.
Coordination of all personnel activities occurred within
the Administration Unit of CERID. This group managed personnel decisions, addressing University quarantine and activity ‘pauses’, and communication with
all University divisions and leadership. Reassignment
of job responsibilities, additional training and competence documentation constituted the majority of the responsibilities handled by this unit.
The Financial Unit was critical in ensuring that costs associated with the surveillance program were captured
and managed. An initial investment of $500,000 by the
University of Louisville President and the Executive
Vice President for Research and Innovation enabled the
operation to begin while community and grant support
was explored and captured. This Unit was also responsible for providing ongoing reports concerning the financial impact on the entire CERID enterprise, including current research outside of COVID-19 response.

Discussion
The UofL CERID leadership team set specific goals
for the LCSP that included: 1) increasing the COVID19 testing capacity for Kentucky and southern Indiana (Kentuckiana); 2) providing an ability to study
the burden of the COVID-19 pandemic on the local
population; and 3) supporting healthcare facilities as
they developed local policies guiding their responses
to COVID-19 in patients and healthcare workers.
Between late February and early March, there was considerable concern regarding a lack of COVID-19 testing capacity in Louisville and across Kentucky. Without access to testing, the healthcare infrastructure and
healthcare workers remained at tremendous risk. In
Louisville, healthcare is a primary industry with 10
area hospitals, more than 45 long-term care facilities,
headquarters for health insurers and pharmaceutical
companies, and specialty centers for cancer, HIV, and
trauma care. This level of healthcare industry present
in the community led to recognition of the importance
of protecting this element of the workforce and economy by early testing and disease recognition. As the
LCSP program was conceptualized then implemented,
with the financial support of UofL President Bendapudi, all aspects of the program were clearly focused on
healthcare facilities and healthcare workers. The University provided space and CERID assumed responsibility for identifying and training the necessary personnel for activities within the scope of practice and com-
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petence. For testing capacity, specialists in the area of
virology with expertise in high-capacity testing platforms helped define the new process. Research meetings began with outreach across the University along
with development of white papers and grant submissions. As an example, the focus on healthcare personnel surveillance and testing was submitted to the
Centers for Disease Control and Prevention on March
25, just 12 days after LCSP implementation. Broad
and transparent collaboration and sharing occurred to
encourage engagement across the University campus
communities. With the breadth of activities, there have
been challenges at every step. During this time of
healthcare, economic, and social disruption, it has been
challenging to infuse a sense of normalcy. Reliance
upon existing systems has been challenging, but using existing relationships and professional connections
have enabled progress and quality outcomes. The real
consequences of using a new process for COVID-19
testing, along with shortages in the supply chain, and
using just-in-time training for new personnel to obtain
specimens, were challenges to understanding all the results and conveying them in the context of clinical relevance.
After six weeks of operation, more than 5000 samples
were tested with more than 730 positive patients and
healthcare workers being identified. Samples were received from fifteen hospitals and seventeen long-term
care facilities in the Kentuckiana area. The operation involved faculty time from Infectious Diseases,
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Laboratory Medicine, Microbiology, Virology, and Research & Innovation. More than 30 CERID personnel
played a role in the processes, in addition to staff representing other areas of the University such as building
security, maintenance and Environmental Health and
Safety. The operational costs, not including laboratory
supplies and laboratory personnel, have been approximately $50,000 per week.
There are several lessons learned from this process that
can be of help to others as they address the challenges
posed by the COVID-19 pandemic. First, the process
is applicable to other testing methods beyond highcapacity testing. Most of the same steps outlined here
can help with traditional laboratory processes when
test request capacity exceeds historic capabilities. Second, success with a new approach during a time of
chaos and upheaval can be achieved when there is an
ability to rely upon existing systems and staff knowledge. Experiences with research processes, database
development, just-in-time training, attention to detail,
and innovation were critical elements. Third, developing a vital public health response requires an ability to
seek and nurture new partners with shared interests.
For the LCSP team, methods to best address the ongoing challenges of the COVID-19 pandemic required
that existing relationships and capacities be maximized
and there be a continuous focus on supporting the
healthcare infrastructure and safety of the healthcare
workforce.
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